Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients' lives.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/06/22 | $625,000,000 | Series D | ||
| 10/04/24 | $17,500,000 | Grant |
IBMSC | undisclosed |
